SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy

NCT04878107 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Camrelizumab
DRUG: Apatinib
DRUG: Docetaxel injection
RADIATION: SBRT
RADIATION: LDRT

Sponsor

Wuhan University